AVDL News and Press, Avadel Pharmaceuticals plc From 11/09/22

LUMRYZ™ granted tentative approval on July 18, confirming its safety profile and clinical efficacy Final approval decision of LUMRYZ expected by June 2023; advancing strategy to potentially accelerate final approval Commercial launch planned for no later t...

DUBLIN, Ireland, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to ...

DUBLIN, Ireland, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:00 a.m. ET on Wednesday, November 9, 2022...

- Results identify mood, sleep and pain disorders as the most common comorbidities in people living with narcolepsy - - Encore presentations at ANA 2022 reinforce positive data from completed Phase 3 REST-ON trial and patient and clinician preference for once-nightly over twice-...

DUBLIN, Ireland, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the Ladenburg Thalmann Healthcar...

Summary Avadel Pharmaceuticals' LUMRYZ (FT218), with its essential once daily dosing, has snagged a tentative approval from the FDA. Once finally approved, LUMRYZ has serious prospects for knocking off Jazz's flawed blockbuster XYREM/XYWAV duopoly. Tentative approval does not ...

Summary Avadel Pharmaceuticals goes into the spotlight today. This small biopharma company recently got 'tentative' FDA approval for its flagship drug but is still waiting on one patent challenge to move forward to commercialization. How should investors navigate through this ...

Avadel Pharmacueticals ( NASDAQ: AVDL ) has filed for a $500M mixed shelf offering . The filing does not necessarily indicate that a sale has begun, or will occur in the future. The company intends to use the proceeds for general corporate purposes. The of...

The shares of Ireland-based biopharma Avadel Pharmaceuticals plc ( NASDAQ: AVDL ) gained more than 9% Thursday after the company announced that a district judge in Delaware postponed a hearing on its patent dispute with Jazz Pharma ( JAZZ ) related to the latter’s n...

Avadel Pharmaceuticals plc (AVDL) Q2 2022 Earnings Conference Call August 09, 2022, 08:00 AM ET Company Participants Brandi Robinson - Senior Vice President of Corporate Affairs Gregory Divis - Chief Executive Officer Jennifer Gudeman - Vice President of Medical ...